Elevated serum and tissue levels of IL-6 and IL-8 are markers of poor clinical outcome in breast cancer29–32 and, along with CXCL1, both IL-6 and IL-8 have been implicated in TNBC tumor progression in vivo26,28. The gene discussed is CXCL1; the disease is neoplasm.